Cargando…

Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi

The hepatitis B virus (HBV) cannot be removed completely from infected hepatocytes, owing to the presence of intrahepatic covalently closed circular DNA (cccDNA). As chronic hepatitis B (CHB) can progress to cirrhosis and hepatocellular carcinoma (HCC), predicting HCC development in high-risk patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baudi, Ian, Inoue, Takako, Tanaka, Yasuhito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037346/ https://www.ncbi.nlm.nih.gov/pubmed/32023902 http://dx.doi.org/10.3390/ijms21030949

Ejemplares similares

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta
por: Sandmann, Lisa, et al.
Publicado: (2021)

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
por: Zhao, Jing, et al.
Publicado: (2023)

Analytical validation of hepatitis B core‐related antigen (HBcrAg) using dried blood spots (DBS)
por: Shimakawa, Yusuke, et al.
Publicado: (2021)

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
por: Aliabadi, Elmira, et al.
Publicado: (2022)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
por: Ma, Hui, et al.
Publicado: (2016)

HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral
por: Chang, Kuo-Chin, et al.
Publicado: (2022)

First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
por: Xie, Yandi, et al.
Publicado: (2023)

Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels
por: Lam, Yuk-Fai, et al.
Publicado: (2017)

Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
por: Mak, Lung-Yi, et al.
Publicado: (2023)

Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients
por: Liu, Jessica, et al.
Publicado: (2017)

Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon‐α treatment in HBeAg‐positive chronic hepatitis B patients
por: Zhu, Ming‐Yu, et al.
Publicado: (2018)

Significant Correlation Between Grip Strength and m2bpgi in Patients with Chronic Liver Diseases
por: Nishikawa, Hiroki, et al.
Publicado: (2019)

Novel biomarkers for the management of chronic hepatitis B
por: Inoue, Takako, et al.
Publicado: (2020)

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B
por: Bui, Hoang Huu, et al.
Publicado: (2023)

Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C
por: Xu, Hongqin, et al.
Publicado: (2017)

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
por: Saleh, Shereen A, et al.
Publicado: (2020)

Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection
por: Mak, Lung-Yi, et al.
Publicado: (2018)

Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
por: Takemura, Kazuya, et al.
Publicado: (2020)

Galectin-9 in autoimmune hepatitis: Correlation between serum levels of galectin-9 and M2BPGi in patients with autoimmune hepatitis
por: Matsuoka, Naoki, et al.
Publicado: (2019)

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
por: Inoue, Takako, et al.
Publicado: (2023)

Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa
por: Vincent, Jeanne Perpétue, et al.
Publicado: (2022)

Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis
por: Migita, Kiyoshi, et al.
Publicado: (2018)

Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population
por: Kim, Mimi, et al.
Publicado: (2020)

The Role of Hepatitis B Core-Related Antigen
por: Inoue, Takako, et al.
Publicado: (2019)

Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B
por: Watanabe, Takehisa, et al.
Publicado: (2021)

On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy
por: Murata, Ayato, et al.
Publicado: (2020)

Hepatitis B virus and its sexually transmitted infection - an update
por: Inoue, Takako, et al.
Publicado: (2016)

Cross-Protection of Hepatitis B Vaccination among Different Genotypes
por: Inoue, Takako, et al.
Publicado: (2020)

Biological variation and reference change values of serum Mac‐2–binding protein glycosylation isomer (M2BPGi)
por: Choi, Rihwa, et al.
Publicado: (2022)

Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins
por: Hayashi, Sanae, et al.
Publicado: (2021)

Diagnostic performance of Mac‐2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups
por: Nah, Eun‐Hee, et al.
Publicado: (2020)

Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis
por: Migita, Kiyoshi, et al.
Publicado: (2020)

Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection
por: Itoh, S., et al.
Publicado: (2019)

Home-Based Cardiac Rehabilitation (HBCR) In Post-TAVR Patients: A Prospective, Single-Center, Cohort, Pilot Study
por: Bhattal, Gurjaspreet K., et al.
Publicado: (2020)

Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy
por: Inoue, Takako, et al.
Publicado: (2017)

Restoration of type I interferon signaling in intrahepatically primed CD8(+) T cells promotes functional differentiation
por: Kawashima, Keigo, et al.
Publicado: (2021)

Reactivation of Hepatitis B Virus in HBsAg-Negative Patients with Hepatocellular Carcinoma
por: Jang, Jeong Won, et al.
Publicado: (2015)

Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma
por: Sudo, T, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_hrqi0hnl4ga279bef4rru09s1r